Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable patients \>= 18 years of age referred for cardiac catheterization for evaluation of cardiac symptoms ( angina, fatigue, or shortness of breath)~* At least 1 indeterminate stenosis (20-80%), fractional flow reserve (FFR) \>=0.8 and PCI deferred~Exclusion Criteria:~* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) during the index procedure or anticipated within the next month~* acute coronary syndrome or cardiogenic shock~* use of strong inhibitors of CTP3A (i.e. ketoconazole, itraconazole, clarithromycin,nefazodone, nelfinavir, ritonavir, indinavir and saquinavir)~* use of inducers of CYP3A (i.e. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort)~* liver cirrhosis~* sever renal insufficience (i.e. creatinine clearance \< 30mL/min/1.73 m2)~* QTc \> 500 milliseconds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
- Sugar pill (Type: PLACEBO_COMPARATOR): Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).